Anticoagulant medication adherence for cancer‐associated thrombosis: A comparison of LMWH to DOACs
dc.contributor.author | Schaefer, Jordan K. | |
dc.contributor.author | Li, Mengbing | |
dc.contributor.author | Wu, Zhenke | |
dc.contributor.author | Basu, Tanima | |
dc.contributor.author | Dorsch, Michael P. | |
dc.contributor.author | Barnes, Geoffrey D. | |
dc.contributor.author | Carrier, Marc | |
dc.contributor.author | Griggs, Jennifer J. | |
dc.contributor.author | Sood, Suman L. | |
dc.date.accessioned | 2021-02-04T21:55:16Z | |
dc.date.available | 2022-02-04 16:55:15 | en |
dc.date.available | 2021-02-04T21:55:16Z | |
dc.date.issued | 2021-01 | |
dc.identifier.citation | Schaefer, Jordan K.; Li, Mengbing; Wu, Zhenke; Basu, Tanima; Dorsch, Michael P.; Barnes, Geoffrey D.; Carrier, Marc; Griggs, Jennifer J.; Sood, Suman L. (2021). "Anticoagulant medication adherence for cancer‐associated thrombosis: A comparison of LMWH to DOACs." Journal of Thrombosis and Haemostasis 19(1): 212-220. | |
dc.identifier.issn | 1538-7933 | |
dc.identifier.issn | 1538-7836 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/166289 | |
dc.description.abstract | BackgroundLow molecular weight heparin (LMWH) and direct oral anticoagulants (DOACs) are used to treat cancer‐associated thrombosis (CAT). It is not clear if patients are less adherent to LMWH compared to DOACs.ObjectivesTo compare medication persistence and adherence between LMWH and DOACs.Patients/MethodsWe analyzed Optum’s de‐identified Clinformatics® Data Mart Database of privately insured adults with cancer diagnosed between January 2009 and October 2015 who were undergoing chemotherapy, immunotherapy, targeted or hormonal therapies; developed CAT; and were treated with an outpatient anticoagulant. The proportion of days covered (PDC) was calculated from the date of anticoagulant prescription until the anticoagulant was switched, stopped, or the study end. Medication adherence was defined as PDC ≥ 80%, ≥95%, and by comparing the mean PDC.ResultsTwo propensity‐matched groups of 1128 patients were identified. Patient persistence was higher with DOACs compared to LMWH (median 116 days versus 34 days). With adherence defined as PDC ≥ 80%, we found no significant difference (95.6% versus 94.6% adherence with DOACs versus LMWH, P = .33). The mean difference of PDC between the two groups was also similar. With medication adherence defined as PDC ≥ 95%, adherence was evident in 73% of DOAC users and 81% of patients on LMWH (P < .001). Prescription copayments were higher on average for LMWH compared to DOACs (mean $153.61 versus 40.67; standard deviation $306.74 versus $33.11).ConclusionPatients remain on DOACs longer than LMWH, but medication adherence is similar with LMWH. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.publisher | National Comprehensive Cancer Network | |
dc.subject.other | low molecular weight heparin | |
dc.subject.other | direct‐acting oral anticoagulants | |
dc.subject.other | patient compliance | |
dc.subject.other | venous thromboembolism | |
dc.subject.other | duration of therapy | |
dc.title | Anticoagulant medication adherence for cancer‐associated thrombosis: A comparison of LMWH to DOACs | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/166289/1/jth15153_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/166289/2/jth15153.pdf | |
dc.identifier.doi | 10.1111/jth.15153 | |
dc.identifier.doi | https://dx.doi.org/10.7302/212 | |
dc.identifier.source | Journal of Thrombosis and Haemostasis | |
dc.identifier.citedreference | Fang MC, Fan D, Sung SH, et al. Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study. Med Care. 2017; 55: e137 ‐ e143. https://doi.org/10.1097/MLR.0000000000000524 | |
dc.identifier.citedreference | Hisada Y, Geddings JE, Ay C, Mackman N. Venous thrombosis and cancer: from mouse models to clinical trials. J Thromb Haemost. 2015; 13: 1372 ‐ 1382. https://doi.org/10.1111/jth.13009 | |
dc.identifier.citedreference | Cohoon KP, Ransom JE, Leibson CL, et al. Direct medical costs attributable to cancer‐associated venous thromboembolism: A population‐based longitudinal study. Am J Med. 2016; 129 ( 1000 ): e15 – e25. https://doi.org/10.1016/j.amjmed.2016.02.030 | |
dc.identifier.citedreference | Lee AY, Levine MN, Baker RI, et al. Randomized Comparison of Low‐Molecular‐Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer I. Low‐molecular‐weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349: 146 ‐ 153. https://doi.org/10.1056/NEJMoa025313 | |
dc.identifier.citedreference | Lee AYY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA. 2015; 314: 677 ‐ 686. https://doi.org/10.1001/jama.2015.9243 | |
dc.identifier.citedreference | Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180‐day period. Clin Appl Thromb Hemost. 2006; 12: 389 ‐ 396. https://doi.org/10.1177/1076029606293692 | |
dc.identifier.citedreference | Hull RD, Pineo GF, Brant RF, et al. Long‐term low‐molecular‐weight heparin versus usual care in proximal‐vein thrombosis patients with cancer. Am J Med. 2006; 119: 1062 ‐ 1072. https://doi.org/10.1016/j.amjmed.2006.02.022 | |
dc.identifier.citedreference | Streiff MB, Holmstrom B, Angelini D NCCN guidelines insights: Cancer‐Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018; 16: 1289 ‐ 1303. https://doi.org/10.6004/jnccn.2018.0084 | |
dc.identifier.citedreference | Kahale LA, Hakoum MB, Tsolakian IG, et al. Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018; 6: CD006650. https://doi.org/10.1002/14651858.CD006650.pub5 | |
dc.identifier.citedreference | Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer‐associated venous thromboembolism. N Engl J Med. 2018; 378: 615 ‐ 624. https://doi.org/10.1056/NEJMoa1711948 | |
dc.identifier.citedreference | Young A, Phillips J, Hancocks H, et al. OC‐11 ‐ Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thromb Res. 2016; 140 ( Suppl 1 ): S172 ‐ S173. https://doi.org/10.1016/S0049‐3848(16)30128‐1 | |
dc.identifier.citedreference | McBane RD 2nd, Wysokinski WE, Le‐Rademacher JG, et al. Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020; 18: 411 ‐ 421. https://doi.org/10.1111/jth.14662 | |
dc.identifier.citedreference | Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low‐molecular‐weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta‐analysis. Thromb Res. 2019; 173: 158 ‐ 163. https://doi.org/10.1016/j.thromres.2018.02.144 | |
dc.identifier.citedreference | Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020; 382: 1599 ‐ 1607. https://doi.org/10.1056/NEJMoa1915103 | |
dc.identifier.citedreference | Cancer‐Associated Venous Thromboembolic Disease. Version 1.2020 edn. National Comprehensive Cancer Network; 2020. | |
dc.identifier.citedreference | Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020; 38: 496 ‐ 520. https://doi.org/10.1200/JCO.19.01461 | |
dc.identifier.citedreference | Cancer Therapy Look‐up Tables. Cancer Research Network. | |
dc.identifier.citedreference | Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high‐risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013; 119: 648 ‐ 655. https://doi.org/10.1002/cncr.27772 | |
dc.identifier.citedreference | Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012; 21 ( Suppl 1 ): 154 ‐ 162. https://doi.org/10.1002/pds.2341 | |
dc.identifier.citedreference | Sanfilippo KM, Wang TF, Gage BF, Liu W, Carson KR. Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. Thromb Res. 2015; 135: 616 ‐ 620. https://doi.org/10.1016/j.thromres.2015.01.012 | |
dc.identifier.citedreference | Heckbert SR, Kooperberg C, Safford MM, et al. Comparison of self‐report, hospital discharge codes, and adjudication of cardiovascular events in the Women’s Health Initiative. Am J Epidemiol. 2004; 160: 1152 ‐ 1158. https://doi.org/10.1093/aje/kwh314 | |
dc.identifier.citedreference | White RH, Garcia M, Sadeghi B, et al. Evaluation of the predictive value of ICD‐9‐CM coded administrative data for venous thromboembolism in the United States. Thromb Res. 2010; 126: 61 ‐ 67. https://doi.org/10.1016/j.thromres.2010.03.009 | |
dc.identifier.citedreference | Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD‐9‐CM and ICD‐10 administrative data. Med Care. 2005; 43: 1130 ‐ 1139. https://doi.org/10.1097/01.mlr.0000182534.19832.83 | |
dc.identifier.citedreference | Desai RJ, Solomon DH, Shadick N, Iannaccone C, Kim SC. Identification of smoking using Medicare data–a validation study of claims‐based algorithms. Pharmacoepidemiol Drug Saf. 2016; 25: 472 ‐ 475. https://doi.org/10.1002/pds.3953 | |
dc.identifier.citedreference | Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373 ‐ 383. https://doi.org/10.1016/0021‐9681(87)90171‐8 | |
dc.identifier.citedreference | Hershman DL, Tsui J, Wright JD, Coromilas EJ, Tsai WY, Neugut AI. Household net worth, racial disparities, and hormonal therapy adherence among women with early‐stage breast cancer. J Clin Oncol. 2015; 33: 1053 ‐ 1059. https://doi.org/10.1200/JCO.2014.58.3062 | |
dc.identifier.citedreference | Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008; 11: 44 ‐ 47. https://doi.org/10.1111/j.1524‐4733.2007.00213.x | |
dc.identifier.citedreference | Gillespie CW, Morin PE, Tucker JM, Purvis L. Medication adherence, health care utilization, and spending among privately insured adults with chronic conditions in the United States, 2010–2016. Am J Med. 2020; 133: 690 ‐ 704. e19. https://doi.org/10.1016/j.amjmed.2019.12.021 | |
dc.identifier.citedreference | Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011; 46: 399 ‐ 424. https://doi.org/10.1080/00273171.2011.568786 | |
dc.identifier.citedreference | Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016; 149: 315 ‐ 352. https://doi.org/10.1016/j.chest.2015.11.026 | |
dc.working.doi | 10.7302/212 | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.